HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

Geetha Shanmugam; Sudeshna Rakshit; Koustav Sarkar

doi:10.1016/j.tranon.2021.101312

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

Transl Oncol. 2022 Feb:16:101312. doi: 10.1016/j.tranon.2021.101312. Epub 2021 Dec 16.

Authors

Geetha Shanmugam¹, Sudeshna Rakshit¹, Koustav Sarkar²

Affiliations

¹ Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India.
² Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India. Electronic address: koustavsarkar@gmail.com.

Abstract

Histone deacetylases (HDACs) are enzymes that play a key role in the epigenetic regulation of gene expression by remodeling chromatin. Inhibition of HDACs is a prospective therapeutic approach for reversing epigenetic alteration in several diseases. In preclinical research, numerous types of HDAC inhibitors were discovered to exhibit powerful and selective anticancer properties. However, such research has revealed that the effects of HDAC inhibitors may be far broader and more intricate than previously thought. This review will provide insight into the HDAC inhibitors and their mechanism of action with special emphasis on the significance of HDAC inhibitors in the treatment of Chronic Obstructive Pulmonary Disease and lung cancer. Nanocarrier-mediated HDAC inhibitor delivery and new approaches for targeting HDACs are also discussed.

Keywords: Chronic obstructive pulmonary disease; Epigenetic regulation; HDAC inhibitors; Histone deacetylases; Lung cancer; Nanocarrier-mediated HDAC inhibitor delivery.

Publication types

Review